1. Home
  2. RYTM vs HIW Comparison

RYTM vs HIW Comparison

Compare RYTM & HIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • HIW
  • Stock Information
  • Founded
  • RYTM 2008
  • HIW 1978
  • Country
  • RYTM United States
  • HIW United States
  • Employees
  • RYTM N/A
  • HIW N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • HIW Real Estate Investment Trusts
  • Sector
  • RYTM Health Care
  • HIW Real Estate
  • Exchange
  • RYTM Nasdaq
  • HIW Nasdaq
  • Market Cap
  • RYTM 3.1B
  • HIW 3.4B
  • IPO Year
  • RYTM 2017
  • HIW 1994
  • Fundamental
  • Price
  • RYTM $59.03
  • HIW $31.87
  • Analyst Decision
  • RYTM Strong Buy
  • HIW Hold
  • Analyst Count
  • RYTM 10
  • HIW 5
  • Target Price
  • RYTM $62.30
  • HIW $31.20
  • AVG Volume (30 Days)
  • RYTM 701.0K
  • HIW 1.2M
  • Earning Date
  • RYTM 11-05-2024
  • HIW 10-22-2024
  • Dividend Yield
  • RYTM N/A
  • HIW 6.24%
  • EPS Growth
  • RYTM N/A
  • HIW 3.74
  • EPS
  • RYTM N/A
  • HIW 1.34
  • Revenue
  • RYTM $112,530,000.00
  • HIW $829,290,000.00
  • Revenue This Year
  • RYTM $63.95
  • HIW N/A
  • Revenue Next Year
  • RYTM $43.24
  • HIW $0.10
  • P/E Ratio
  • RYTM N/A
  • HIW $23.98
  • Revenue Growth
  • RYTM 81.55
  • HIW N/A
  • 52 Week Low
  • RYTM $31.53
  • HIW $17.58
  • 52 Week High
  • RYTM $68.58
  • HIW $36.78
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 55.82
  • HIW 37.54
  • Support Level
  • RYTM $55.37
  • HIW $30.91
  • Resistance Level
  • RYTM $60.79
  • HIW $34.22
  • Average True Range (ATR)
  • RYTM 3.60
  • HIW 0.67
  • MACD
  • RYTM -0.27
  • HIW -0.20
  • Stochastic Oscillator
  • RYTM 52.59
  • HIW 29.00

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

About HIW Highwoods Properties Inc.

Highwoods Properties Inc is a real estate investment trust engaged in the acquisition, ownership, management, and leasing of properties in urban areas throughout the Southern United States. In terms of total square footage, the vast majority of the company's real estate portfolio comprises office buildings in terms. Highwoods Properties derives nearly all of its income in the form of rental revenue from the tenants of its buildings. The majority of this revenue comes from its holdings in the urban markets of Atlanta, Raleigh, Nashville, and Tampa. These cities also account for the majority of the square footage under the company's ownership. Highwoods Properties' largest customers include the U.S. Government, financial services firms, industrial supply retailers, and healthcare companies.

Share on Social Networks: